Title |
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
|
---|---|
Published in |
Nature Communications, March 2018
|
DOI | 10.1038/s41467-018-03099-x |
Pubmed ID | |
Authors |
Julie George, Vonn Walter, Martin Peifer, Ludmil B. Alexandrov, Danila Seidel, Frauke Leenders, Lukas Maas, Christian Müller, Ilona Dahmen, Tiffany M. Delhomme, Maude Ardin, Noemie Leblay, Graham Byrnes, Ruping Sun, Aurélien De Reynies, Anne McLeer-Florin, Graziella Bosco, Florian Malchers, Roopika Menon, Janine Altmüller, Christian Becker, Peter Nürnberg, Viktor Achter, Ulrich Lang, Peter M. Schneider, Magdalena Bogus, Matthew G. Soloway, Matthew D. Wilkerson, Yupeng Cun, James D. McKay, Denis Moro-Sibilot, Christian G. Brambilla, Sylvie Lantuejoul, Nicolas Lemaitre, Alex Soltermann, Walter Weder, Verena Tischler, Odd Terje Brustugun, Marius Lund-Iversen, Åslaug Helland, Steinar Solberg, Sascha Ansén, Gavin Wright, Benjamin Solomon, Luca Roz, Ugo Pastorino, Iver Petersen, Joachim H. Clement, Jörg Sänger, Jürgen Wolf, Martin Vingron, Thomas Zander, Sven Perner, William D. Travis, Stefan A. Haas, Magali Olivier, Matthieu Foll, Reinhard Büttner, David Neil Hayes, Elisabeth Brambilla, Lynnette Fernandez-Cuesta, Roman K. Thomas |
Abstract |
Pulmonary large-cell neuroendocrine carcinomas (LCNECs) have similarities with other lung cancers, but their precise relationship has remained unclear. Here we perform a comprehensive genomic (n = 60) and transcriptomic (n = 69) analysis of 75 LCNECs and identify two molecular subgroups: "type I LCNECs" with bi-allelic TP53 and STK11/KEAP1 alterations (37%), and "type II LCNECs" enriched for bi-allelic inactivation of TP53 and RB1 (42%). Despite sharing genomic alterations with adenocarcinomas and squamous cell carcinomas, no transcriptional relationship was found; instead LCNECs form distinct transcriptional subgroups with closest similarity to SCLC. While type I LCNECs and SCLCs exhibit a neuroendocrine profile with ASCL1high/DLL3high/NOTCHlow, type II LCNECs bear TP53 and RB1 alterations and differ from most SCLC tumors with reduced neuroendocrine markers, a pattern of ASCL1low/DLL3low/NOTCHhigh, and an upregulation of immune-related pathways. In conclusion, LCNECs comprise two molecularly defined subgroups, and distinguishing them from SCLC may allow stratified targeted treatment of high-grade neuroendocrine lung tumors. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 14 | 30% |
United Kingdom | 3 | 6% |
Spain | 3 | 6% |
France | 3 | 6% |
Sweden | 1 | 2% |
Switzerland | 1 | 2% |
Ireland | 1 | 2% |
Portugal | 1 | 2% |
New Zealand | 1 | 2% |
Other | 0 | 0% |
Unknown | 19 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 25 | 53% |
Scientists | 12 | 26% |
Practitioners (doctors, other healthcare professionals) | 8 | 17% |
Science communicators (journalists, bloggers, editors) | 2 | 4% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 208 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 44 | 21% |
Student > Ph. D. Student | 26 | 13% |
Other | 17 | 8% |
Student > Master | 14 | 7% |
Student > Doctoral Student | 9 | 4% |
Other | 27 | 13% |
Unknown | 71 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 50 | 24% |
Biochemistry, Genetics and Molecular Biology | 43 | 21% |
Agricultural and Biological Sciences | 13 | 6% |
Immunology and Microbiology | 5 | 2% |
Computer Science | 4 | 2% |
Other | 11 | 5% |
Unknown | 82 | 39% |